These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19179557)

  • 1. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features.
    Loriot Y; Massard C; Gross-Goupil M; Di Palma M; Escudier B; Bossi A; Fizazi K
    Ann Oncol; 2009 Apr; 20(4):703-8. PubMed ID: 19179557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer.
    Jeske S; Tagawa ST; Olowokure O; Selzer J; Giannakakou P; Nanus DM
    Urol Oncol; 2011; 29(6):676-81. PubMed ID: 20451413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial.
    Fléchon A; Pouessel D; Ferlay C; Perol D; Beuzeboc P; Gravis G; Joly F; Oudard S; Deplanque G; Zanetta S; Fargeot P; Priou F; Droz JP; Culine S
    Ann Oncol; 2011 Nov; 22(11):2476-2481. PubMed ID: 21436186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of carboplatin in combination with paclitaxel in patients with castration-resistant prostate cancer.
    Rusarova N; Vitaskova D; Kalabova H; Ondruskova A; Purova D; Melichar B; Studentova H
    Future Oncol; 2022 Dec; 18(38):4183-4192. PubMed ID: 36519589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue Chromogranin A Expression during Prostate Cancer Progression: Prediction of Chemosensitivity.
    Mitsui Y; Arichi N; Hiraki M; Harada Y; Yasumoto H; Shiina H
    Urol J; 2015 Jul; 12(3):2165-72. PubMed ID: 26135933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Salvage therapy for castration-refractory prostate cancer resistant to docetaxel].
    Takayama T; Sugiyama T; Furuse H; Yajima T; Suzuki T; Kai F; Nagata M; Otsuka A; Ishii Y; Ozono S
    Nihon Hinyokika Gakkai Zasshi; 2013 Nov; 104(6):681-7. PubMed ID: 24564074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel, estramustine phosphate and carboplatin for castration-resistant prostate cancer.
    Narita S; Tsuchiya N; Yuasa T; Maita S; Obara T; Numakura K; Tsuruta H; Saito M; Inoue T; Horikawa Y; Satoh S; Habuchi T
    Int J Clin Oncol; 2012 Jun; 17(3):204-11. PubMed ID: 21706123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
    Oh WK; Hagmann E; Manola J; George DJ; Gilligan TD; Jacobson JO; Smith MR; Kaufman DS; Kantoff PW
    Clin Cancer Res; 2005 Jan; 11(1):284-9. PubMed ID: 15671557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly low-dose docetaxel combined with estramustine and dexamethasone for Japanese patients with metastatic castration-resistant prostate cancer.
    Hatano K; Nishimura K; Nakai Y; Yoshida T; Sato M; Kawashima A; Mukai M; Nagahara A; Uemura M; Oka D; Nakayama M; Takayama H; Shimizu K; Meguro N; Tanigawa T; Yamaguchi S; Tsujimura A; Nonomura N
    Int J Clin Oncol; 2013 Aug; 18(4):704-10. PubMed ID: 22688162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer.
    Nakabayashi M; Sartor O; Jacobus S; Regan MM; McKearn D; Ross RW; Kantoff PW; Taplin ME; Oh WK
    BJU Int; 2008 Feb; 101(3):308-12. PubMed ID: 18184327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.
    Picus J; Halabi S; Kelly WK; Vogelzang NJ; Whang YE; Kaplan EB; Stadler WM; Small EJ;
    Cancer; 2011 Feb; 117(3):526-33. PubMed ID: 20862750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer.
    Reuter CW; Morgan MA; Ivanyi P; Fenner M; Ganser A; Grünwald V
    World J Urol; 2010 Jun; 28(3):391-8. PubMed ID: 20229232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer.
    Sella A; Yarom N; Zisman A; Kovel S
    Oncology; 2009; 76(6):442-6. PubMed ID: 19420966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of docetaxel weekly in combination with carboplatin every 3 weeks as first-line chemotherapy in stage IIB to stage IV epithelial ovarian cancer.
    Sorbe B; Graflund M; Horvath G; Swahn M; Boman K; Bangshöj R; Lood M; Malmström H
    Int J Gynecol Cancer; 2012 Jan; 22(1):47-53. PubMed ID: 22193643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
    Oh WK; Halabi S; Kelly WK; Werner C; Godley PA; Vogelzang NJ; Small EJ;
    Cancer; 2003 Dec; 98(12):2592-8. PubMed ID: 14669278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients.
    Buonerba C; Federico P; Bosso D; Puglia L; Policastro T; Izzo M; Perri F; Vittoria Scarpati GD; Ferro M; Cobelli OD; De Placido S; Aieta M; Imbimbo C; Longo N; Di Lorenzo G
    Future Oncol; 2014 Jun; 10(8):1353-60. PubMed ID: 25052746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Carboplatin Plus Paclitaxel as the First-, Second-, and Third-line Chemotherapy in Men With Castration-resistant Prostate Cancer.
    Fujiwara M; Akamatsu S; Sumiyoshi T; Segawa T; Mizuno K; Yoshino T; Goto T; Sawada A; Saito R; Kobayashi T; Yamasaki T; Inoue T; Ogawa O
    Clin Genitourin Cancer; 2019 Oct; 17(5):e923-e929. PubMed ID: 31307917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study.
    Mahammedi H; Planchat E; Pouget M; Durando X; Curé H; Guy L; Van-Praagh I; Savareux L; Atger M; Bayet-Robert M; Gadea E; Abrial C; Thivat E; Chollet P; Eymard JC
    Oncology; 2016; 90(2):69-78. PubMed ID: 26771576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.
    Fizazi K; Beuzeboc P; Lumbroso J; Haddad V; Massard C; Gross-Goupil M; Di Palma M; Escudier B; Theodore C; Loriot Y; Tournay E; Bouzy J; Laplanche A
    J Clin Oncol; 2009 May; 27(15):2429-35. PubMed ID: 19364971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.